Nuvalent Presents New Preclinical Data For HER2-Selective Inhibitor, NVL-330, And ROS1-Selective Inhibitor, Zidesamtinib, At AACR Annual Meeting 2024
Nuvalent Presents New Preclinical Data For HER2-Selective Inhibitor, NVL-330, And ROS1-Selective Inhibitor, Zidesamtinib, At AACR Annual Meeting 2024
Nuvalent 在 2024 年 AACR 年会上公布了 HER2 选择性抑制剂 NVL-330 和 ROS1 选择性抑制剂齐德沙替尼的新临床前数据
Preclinical data continue to support NVL-330's broad activity against HER2 oncogenic alterations, selectivity over wild-type EGFR, and differentiated brain-penetrant profile
临床前数据继续支持 NVL-330 对 HER2 致癌变异的广泛活性、对野生型 EGFR 的选择性以及差异化的大脑穿透特征
Zidesamtinib shown to be effective at suppressing on-target ROS1 resistance mutations in preclinical mutagenesis screens
Zidesamtinib在临床前诱变筛查中显示可有效抑制靶向ROS1耐药突变